ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "clinical trials and ulcers"

  • Abstract Number: 1791 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics

    Gulen Hatemi1, Alfred Mahr2, Mitsuhiro Takeno3, Do-Young Kim4, Melike Melikoglu1, Sue Cheng5, Shannon McCue5, Maria Paris5, Mindy Chen5 and Yusuf Yazici6, 1Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 2Hospital Saint-Louis, University Paris Diderot, Paris, France, 3Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Korea, Republic of (South), 5Celgene Corporation, Summit, NJ, 6New York University School of Medicine, New York, NY

    Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU) that can be disabling and negatively affect quality of life.…
  • Abstract Number: 2789 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study

    Gulen Hatemi1, Alfred Mahr2, Yoshiaki Ishigatsubo3, Yeong Wook Song4, Melike Melikoglu5, Sue Cheng6, Shannon McCue6, Maria Paris6, Mindy Chen6 and Yusuf Yazici7, 1Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey, 2Hospital Saint-Louis, University Paris Diderot, Paris, France, 3Yokohama City University Graduate School of Medicine, Yokohama, Japan, 4Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), 5Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 6Celgene Corporation, Summit, NJ, 7New York University School of Medicine, New York, NY

    Background/Purpose: Behçet’s syndrome is a chronic, relapsing, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU), which can be disabling and substantially impact quality of…
  • Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting

    Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup

    Mitsuhiro Takeno1, Yoshiya Tanaka2, Hajime Kono3, Shouji Sugii4, Mitsumasa Kishimoto5, Sue Cheng6, Shannon McCue6, Maria Paris6 and Hiroaki Dobashi7, 1Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 4Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 5Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 6Celgene Corporation, Summit, NJ, 7Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…
  • Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting

    Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study

    Peter C. Grayson1, Yusuf Yazici2, Elaine Novakovich3, Elizabeth Joyal4, Raphaela T. Goldbach-Mansky4 and Cailin H. Sibley3,5, 1NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, 2Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3National Institutes of Health Clinical Center, Bethesda, MD, 4NIAMS, National Institutes of Health Clinical Center, Bethesda, MD, 5Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

    Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences